Currently unavailable.
In October 2018, the world's first RNAi drug Patisiran (trade name ONPATTRO®) was approved by the US FDA for the treatment of hereditary thyroxine-mediated amyloidosis polyneuropathy. https://rna.bocsci.com/support..../what-are-rna-drugs.